Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 58Terminated 13Unknown 6Recruiting 5Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 1

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1Testosterone Propionate 1Testosterone 1Temozolomide 1TPI-287 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Everolimus × Clear all
NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Southern Europe New Drug Organization

Phase 1/2 Suspended
45 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡